Isolation of cross-reacting compounds to Incstar Cyclo-Trac SP RIA in blood samples obtained from cardiac allograft patients on cyclosporine therapy.
To examine the specificity of the Incstar Cyclo-Trac SP RIA kit, individual blood samples from 28 cardiac allograft patients on cyclosporine A (CsA) therapy were extracted and chromatographed by HPLC. Initially, eluates from a pool of the above samples were collected at regular intervals and measured by RIA to locate possible cross-reacting compounds. Unknown cross-reacting materials were detected in a fraction (UNK) that was collected before elution of CsA. For each patient's sample, fraction UNK and the fraction containing CsA were then collected and measured by RIA. In 9 of 28 samples, cross-reactivity was detected in fraction UNK; range 11 to 36%, mean 22 +/- 7.5%. Cross-reactivity was not apparent in fraction UNK of CsA-free blood samples from normal volunteers.
Loo
J C
JC
Bureau of Drug Research, Ottawa Civic Hospital, Ontario, Canada.
Gallicano
K D
KD
McGilveray
I J
IJ
Beaudoin
N
N
Jindal
S L
SL
D000918:Antibody Specificity; D001774:Blood Chemical Analysis / Q000379:methods; D002851:Chromatography, High Pressure Liquid; D003429:Cross Reactions; D003524:Cyclosporins / Q000097:blood* / Q000276:immunology / Q000627:therapeutic use; D016027:Heart Transplantation; D006801:Humans; D011863:Radioimmunoassay / Q000379:methods*
D003524:Cyclosporins